modulatory effects of metformin alone and in combination with cimetidine and ibuprofen on t cell-related parameters in a breast cancer model

Metformin, cimetidine, and ibuprofen separately exhibit immunomodulatory and antitumorigenic effects. herein, the impacts of metformin alone and in combination with cimetidine/ibuprofen on some th1- and regulatory t (treg) cell-related parameters were evaluated using a breast cancer (bc) model. for establishing the bc model, four groups of balb/c mice were challenged with the carcinoma cell line. after 11-30 days post-induction, they were treated intraperitoneally (with metformin (200 mg/kg), metformin plus cimetidine (20 mg/kg); metformin plus ibuprofen (20 mg/kg), or with all three drugs in mentioned doses. untreated bc and without tumor mice were enrolled as control groups. on day 31, splenic th1 and treg cell frequencies, serum interferongamma (ifn-γ), and transforming growth factor-beta (tgf-β) concentration, and intra-tumoral t-bet, tgf-β, and forkhead box protein p3 (foxp3) expression were measured; using flow cytometry, enzyme-linked immunosorbent assay (elisa), and real-time-pcr, respectively. treatment of the bc mice with metformin alone and in combination with cimetidine and/or ibuprofen enhanced the frequency of th1 cells, and ifn-γ concentration, while it resulted in a decrease in the frequency of treg cells, serum tgf-β concentration, and the expression of foxp3 and tgf-β compared with un-treated bc mice. foxp3 expression in the metformintreated group was lower in mice who received combination therapy. survival rate and body weight were increased, while tumor size and spleen index were reduced in mice treated with metformin alone and its combination with cimetidine and/or ibuprofen. no remarkable differences were found between metformin-treated mice and those who received combination therapies regarding th1 and treg cell percentages, tgf-β expression, body weight, tumor size, and spleen index. the benefits of combinational therapy may be largely attributed to metformin. immunotherapeutic potentials of metformin in cancers need further considerations.